Tamarind Bio

Based in the US, Tamarind Bio, Inc. operates a no-code cloud platform for computational biology, facilitating the design and optimization of protein therapeutics and peptides using advanced AI methodologies. Founded in 2023 in San Francisco, US, by CEO Deniz Kavi and CTO Sherry Liu, Tamarind Bio, Inc. specializes in computational biology solutions. . Tamarind Bio offers a no-code cloud platform specifically designed for computational biology, enabling users to create and optimize protein therapeutics, industrial enzymes, and peptides. The platform leverages advanced artificial intelligence and physics-based methodologies to facilitate the design of improved variants, de novo binders, and novel molecules without the need for extensive setup or literature reviews. By utilizing state-of-the-art tools such as AlphaFold, RFdiffusion, and GROMACS, Tamarind Bio addresses significant challenges in the biopharmaceutical sector, allowing researchers to predict protein structures, redesign antibody complementarity-determining regions (CDRs), and optimize sequences based on various developability properties. The company serves a diverse client base, including pharmaceutical companies, academic institutions, and biotechnology firms operating primarily in North America and Europe. Their products are designed for use by scientists seeking efficient and scalable solutions in protein engineering, thus enhancing productivity and innovation in drug development. Tamarind Bio generates revenue through a subscription-based model that allows clients to access its suite of computational tools via a web interface or API. Clients typically engage with the platform on a contractual basis, with pricing structures tailored to the specific needs of each customer, which may include different tiers of access based on the volume of computations. The primary revenue stream is derived from the usage of flagship services, including antibody design and peptide discovery tools, where customers can input large datasets and receive comprehensive analyses and predictions. The company’s SOC 2 compliant, secure cloud infrastructure ensures that clients maintain ownership of their data while benefiting from the software's capabilities, thereby fostering a trusting relationship with life sciences companies that seek reliable and innovative solutions in protein research.

1. Series A

   Feb 24, 2026

   Amount

   $12M

   Investors

   Locked

2. Series A

   May 2, 2025

   Amount

   $14M

   Investors

   Locked